(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number
WO 02/096894 A1

(51) International Patent Classification[7]: C07D 277/56, 409/06, A61K 31/426

(21) International Application Number: PCT/EP02/05885

(22) International Filing Date: 29 May 2002 (29.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0113233.1 31 May 2001 (31.05.2001) GB

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DUMAITRE, Bernard, Andre** [FR/FR]; Laboratoire GlaxoSmithKline, Centre de Recherches, Z.A. de Courtaboeuf, 25, avenue de Quebec, F-91940 Les Ulis (FR). **GOSMINI, Romain, Luc, Marie** [FR/FR]; Laboratoire GlaxoSmithKline, Centre de Recherches,, Z.A. de Courtabouef, 25, avenue du Quebec, F-91951 Les Ulis (FR).

(74) Agent: **LEAROYD, Stephanie, Anne**; GlaxoSmithKline, Corporate Intellectual Property (CN9.25.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THIAZOLE OR OXAZOLE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT OF CARDIOVASCULAR AND RELATED DISEASES



(I)

(57) Abstract: A compound of formula (1) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof: wherein R^1 and R^2 are independently H or C_{1-3} alkyl or R^1 and R^2 which are bonded to the same carbon atom may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; X_1 represents O or S; Each R^3, R^4, R^8 and R^9 independently represents H, halogen, $-CH_3$ and OCH_3; R^5 represents H or C_{1-6} alkyl or R^4 and R^5 together form a 3-6 membered cycloalkyl ring. X_2 represents NH, NCH_3 or O; One of Y and Z is N, and the other is O or S; R^6 represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one more halogen, CF_3, C_{1-6} straight or branched alkyl (optionally substituted by halogen), with the provision that when R^6 is pyridyl, the N is unsubstituted. R^7 represents C_{1-6} alkyl, (optionally substituted by one or halogens), $-C_{0-6}$ alkyl-5 membered heteroaryl C_{0-6} alkyl $(O)_n$- phenyl, wherein n is 0 or 1, with the proviso that when R^1 and R^2 are methyl, R^8 and R^9 are H, R^5 is H, then R^7 cannot be CH_3 or CF_3.

WO 02/096894 A1